INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
https://doi.org/10.15789/1563-0625-2014-6-559-566
Abstract
This clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group received adjuvant chemoimmunotherapy accomplished with Ingaron, whereas 30 cases (48%) in control group were assigned to receive conventional adjuvant chemotherapy. Adjuvant chemoimmunotherapy was administered according to the following schedule: carboplatinum, AUC = 5 i.v. on day 1; etoposide, 100 mg/m2 i.v. on days 1,3,5; interferon-gamma, 500.000 I.E./m2 i.v. on days 2,4,6. In the patiens undergoing lobectomy, carboplatinum was replaced for cisplatinum 100 mg/m2 i.v. on day 1. Comparative evaluation of the both treatment regimens has shown a correcting effect of Ingaron upon cellular immunity links. The Ingaroncontaining chemoimmunotherapy may contribute to improvement of 3-year event-free survival among lung adenocarcinoma patients by 19 percent (p = 0.06607).
About the Authors
S. P. Pyltsin
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD (Medicine), Research Associate, Department of Thoracic Surgery, Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
E. Yu. Zlatnik
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Chief Research Associate, Laboratory of Tumor Immunophenotyping, Rostov/Don Research Institute of Oncology, Russian Ministry
of Health Care, Rostov-on-Don, Russian Federation
Yu. N. Lazutin
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD (Medicine), Associate Professor, Leading Research Associate, Department of Thoracic Surgery, Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
G. Z. Sergostyants
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Chief, Department of Thoracic Surgery, Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
G. I. Zakora
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD (Medicine), Research Associate, Laboratory of Tumor Immunophenotyping, Rostov/Don Research Institute of Oncology, Russian Ministry of Health CareRostov-on-Don,
Russian Federation
I. A. Leyman
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD (Medicine), Physician, Department of Thoracic Surgery, Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
P. A. Anistratov
Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
Russian Federation
Russian Federation
PhD (Medicine), Physician, Department of Thoracic Surgery, Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian Federation
References
1. Абрамов М.Е., Кадагидзе З.Г., Славина Е.Г., Черткова А.И., Личиницер М.Р. Ингарон (интерферон-гамма) в сочетании с химиотерапией в лечении онкологических больных // Фарматека, 2006. Т. 11, № 126. С. 38-42. [Abramov ME, Kadagidze ZG, E. Slavinа, A.I. Chertkova, M.R. Lichinicer Ingaron (interferongamma) in combination with chemotherapy in cancer patients. Farmateka = Farmateka. 2006. Vol. 11, no. 126, pp. 38-42. (In Russ.)]
2. Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы. М.: Геотар, 2005. 356 с. [Ershov F.I., Kiselev O.I. Interferons and their inducers.] Moscow: GEOTAR, 2005. 356 p.]
3. Лазутин Ю.Н., Зинькович С.А., Карташов С.З. Сергостьянц Г.З., Пыльцин С.П., Кабанов С.Н. Адьювантная терапия аденокарциномы легкого // Известия высших учебных заведений. Северо-Кавказский регион. Естественные науки, 2012. № 1. С. 121-125. [Lazutin Yu. N., Zinkovich S.A., Kartashov S.Z., Sergostyants G.Z., Pyltsin S.P., Kabanov S.N. Adjuvant therapy of lung adenocarcinoma. News of Higher Educational Institutions. North Caucasus region. Natural Sciences in 2012. no. 1, pp. 121-125. (In Russ)].
4. Лазутин Ю.Н., Пыльцин С.П., Кабанов С.Н., Мисюренко А.Ю. Результаты адьювантной химио-иммунотерапии аденокарциномы легкого с использованием отечественного рекомбинантного интерферона-гамма-Ингарона // Российский биотерапевтический журнал, 2012. Т. 11, № 2. С. 30. [Lazutin Yu.N., Pyltsin S.P., Kabanov S.N., Misyurenko A.Yu. Results of adjuvant chemoimmunotherapy of lung adenocarcinoma using domestic recombinant interferon-gamma Ingaron. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapeutic, 2012, Vol. 11, no. 2, p. 30. (In Russ.)]
5. Шмелев В. А. Интерферон-гамма, фактор некроза опухолей, тимозин- альфа1- противоинфекционные и противоопухолевые цитокины и препараты. М.: Медпрактика-М, 2008. 535 с. [Shmelev V.A. Interferon-gamma, tumor necrosis factor, thymosin-alpha 1-anti-infective and anti-cancer drugs and cytokines]. Moscow: Medical practice-M, 2008. 535 p.
6. Хорхе Р. Кесада. Биологические методы лечения интерфероном-гамма. В кн: Биологические методы лечения онкологических заболеваний. Под ред. В. Т. ДеВита мл., С. Хеллмана, С. А. Розенберга; пер. с англ. под ред. Л. А. Певницкого. М.: Медицина, 2002. С. 452-459. [Jorge R. Quesada. Biological methods of treatment with interferon-gamma. In the book: Biological treatments for cancer. Ed. VT DeVita jr., S. Hellman, S.A. Rosenberg; lane. from English. ed. LA Pevnitsky.] Moscow: Medicine, 2002, pp. 452-459.
7. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med., 2004, Vol. 350, no. 4, pp. 351-360.
8. Arriagada R., Auperin A., Burdett S., Le Chevalier T., Le Pechoux C., Pignon J.-P., Stewart L.A., Tierney J.F. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet, 2010, Vol. 375, no. 9722, pp. 1267-1277.
9. Chawla-Sarkar M., Linder D.J., Liu Y-F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon- stimulated genes as mediators of apoptosis. Apoptosis, 2003, Vol. 8 , no. 3, pp. 237-249.
10. Douillard J.Y., Rossel R., De Lena M., Carpagnano F., Ramlau R., Gonz les-Larriba J.L., Grodzki T., Pereira J.R., Le Groumellec A., Lorusso V., Clary C., Torres A.J., Dahabreh J., Souquet P.J., Astudillo J., Fournel P., Artal-Cortes A., Jassem J., Koubkova L., His P., Riggi M., Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage 1B-3A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol., 2006, Vol. 7, no. 9, pp. 719-727.
11. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol., 2006, Vol. 6, no. 11, pp. 836-848.
12. Fidler I. J. Regulation of neoplastic angiogenesis. J. Natl. Cancer Inst. Monogr., 2001, Vol. 28, p. 10.
13. Fruh M., Rolland E., Pignon J.P., Seymour L., Ding K., Tribodet H., Winton T., Le Chevalier T., Scagliotti G.V., Douillard J.Y., Spiro S., Shepherd F.A. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J. Clin. Oncol., 2008, Vol. 26, no. 21, pp. 3573-3581.
14. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber RD. Demonstration of an interferon-gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA, 1998, Vol. 95, no. 13, pp. 7556-7561.
15. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., Watanabe Y., Wada H., Tsuboi M., Hamajima N. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med., 2004, Vol. 350, no. 17, pp. 1713-1721.
16. Mattson K., Niiranen A., Pyrhonen S., F rkkilä M., Cantell K. Recombinant interferon gamma treatment in non-small-cell lung cancer. Antitumor effect and cardiotoxicity. Acta Oncol., 1991, Vol. 30, no. 5, pp. 607-610.
17. Platanias L.C. Mechanisms of type-1 and type-2 interferons-mediated signaling. Nat. Rev. Immunol., 2005, Vol. 5, pp. 375-386.
18. Shiller J.H., Storer B., Dreicer R., Rosenquist D., Frontiera M., Carbone P.P. Randomized phase 2-3 trial of combination beta and gamma interferons, and etopozid, and cisplatin in inoperable non-small cell cancer of the lung. J. Natl Cancer Inst. 1989 Nov. 15, Vol. 81, no. 22, pp. 1739-1743.
19. Strauss G.M., Herndon J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., Gillenwater H.H., Watson D.M., Sugarbaker D.J., Schilsky R.L., Vokes E.E., Green M.R. Adjuvant paclitaxel
20. plus carboplatin compared with observation in stage 1B non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol., 2008, Vol. 26, no. 31, pp. 5043-5051.
21. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., Cormier Y., Goss G., Inculet R., Vallieres E., Fry W., Bethune D., Ayoub J., Ding K., Seymour L., Graham B., Tsao M.S., Gandara D., Kesler K., Demmy T., Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med., 2005, Vol. 352, no. 25, pp. 2589-2597.
22. Zimmerer J., Lesinski G.B., Kondadasula S.V., Karpa V.I., Lehman A., Raychaudhury A., Becknell B., Carson W.E. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling protein. J. Immunol., 2007, Vol. 178, no. 8, pp. 4832-4845.
Review
For citations:
Pyltsin S.P., Zlatnik E.Yu., Lazutin Yu.N., Sergostyants G.Z., Zakora G.I., Leyman I.A., Anistratov P.A. INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY. Medical Immunology (Russia). 2014;16(6):559-566. (In Russ.) https://doi.org/10.15789/1563-0625-2014-6-559-566
Views:
1151
Email this article 